Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600184 | 0.86 | LMNA (0.47) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL10123125 | 0.86 | MAPT (0.47) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL8872923 | 0.84 | LMNA (0.46) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL471858 | 0.83 | KDM4E (0.60) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL25345688 | 0.82 | HRH3 (0.49) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL600205 | 0.82 | NPC1 (0.47) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL13349659 | 0.82 | KDM4E (0.46) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL2088974 | 0.78 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL5255964 | 0.76 | IL2 (0.43) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL3942245 | 0.76 | KDM4E (0.53) | LMNAHTTMAPTKDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | AXCESO BIOPHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4215533-B1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AXCESO BIOPHARMA CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4215533-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Axceso Biopharma Co., Ltd. (KR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060094-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엑세쏘바이오파마 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD1, PDCD1LG2, CD274 | LMNA 2765/4885HTT 2120/4885MAPT 1278/4885 |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | PDCD1, CD274, PDCD1LG2 | LMNA 2148/4885HTT 2155/4885MAPT 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.